Frontlight ResearchEarly access
TerminatedNo phase
Evaluation of Effectiveness and Safety of Hybrid Coronary Revascularization
Key facts
- Who runs it
- Seung-Jung Park
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 6 people enrolled
- Started
- 5 Apr 2019
- Ended
- 13 Apr 2026
- Type of study
- Observational
- Treatments tested
- Hybrid Coronary Revascularization
- Record updated
- 15 April 2026
- Why it stopped
- Early termination due to low enrollment
Who can take part
- Age
- 20 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Age 20 and more
- Hybrid coronary revascularization due to multivessel coronary artery disease(must include left anterior descending artery)
- Written consent
Who cannot take part
- Previous CABG(coronary artery bypass graft)
- Life expectancy ≤1 year
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study evaluated the effectiveness and safety of Hybrid Coronary Revascularization in real-world practice.
The group in the trial
- Multivessel coronary artery disease
must include left anterior descending artery
Treatment: Hybrid Coronary Revascularization
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of Effectiveness and Safety of Hybrid Coronary Revascularization, a Non-randomized, Prospective, Open-label Registry in Real-world Practice
- Record updated
- 15 April 2026